Wednesday, September 23, 2026

Charter Comm, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Charter Comm, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Charter Comm, Inc.

7.5% sales growth and 10.64% return on equity

Charter Communications, Inc., through its subsidiaries, provides cable services to residential and commercial customers in the United States.

Charter Comm, Inc.'s sales growth this year is expected to be 5.8% and 5.3% for next year.

Year-on-year quarterly revenue growth grew by 7.3%, now sitting on 48.1B for the twelve trailing months.

Charter Comm, Inc.'s sales growth for the next quarter is 7.5%. The company's growth estimates for the present quarter and the next is 127.4% and 26.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.64%.

Volatility

Charter Comm, Inc.'s last day, last week, and last month's current volatility was 0.32%, 0.43%, and 0.99%, respectively.

Charter Comm, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.50% (day), 1.75% (last week), and 2.35% (last month), respectively.

Charter Comm, Inc.'s Stock Yearly Top and Bottom Value

Charter Comm, Inc.'s stock is valued at $617.10 at 17:22 EST, below its 52-week high of $681.71 and way above its 52-week low of $449.83.

Charter Comm, Inc.'s Moving Average

Charter Comm, Inc.'s worth is under its 50-day moving average of $622.03 and under its 200-day moving average of $630.06.

3. BioDelivery Sciences International, Inc.

17.5% sales growth and 28.89% return on equity

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally.

BioDelivery Sciences International, Inc.'s sales growth this year is expected to be 13.7% and 21% for next year.

Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 156.47M for the twelve trailing months.

BioDelivery Sciences International, Inc.'s sales growth for the next quarter is 17.5%. The company's growth estimates for the present quarter and the next is 40% and 600%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.89%.

Volatility

BioDelivery Sciences International, Inc.'s last day, last week, and last month's current volatility was 1.45%, 2.26%, and 2.73%, respectively.

BioDelivery Sciences International, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.78% (day), 4.11% (last week), and 4.96% (last month), respectively.

BioDelivery Sciences International, Inc.'s Stock Yearly Top and Bottom Value

BioDelivery Sciences International, Inc.'s stock is valued at $3.45 at 17:22 EST, way under its 52-week high of $5.45 and way above its 52-week low of $3.04.

BioDelivery Sciences International, Inc.'s Moving Average

BioDelivery Sciences International, Inc.'s worth is way under its 50-day moving average of $3.89 and way below its 200-day moving average of $3.96.

4. Coca Cola Femsa S.A.B. de C.V.

30.6% sales growth and 8.22% return on equity

Coca-Cola FEMSA, S.A.B. de C.V., a franchise bottler, produces, markets, sells, and distributes Coca-Cola trademark beverages.

Coca Cola Femsa S.A.B. de C.V. 's sales growth this year is anticipated to be 10.7% and 3.7% for next year.

Year-on-year quarterly revenue growth declined by 6.7%, now sitting on 181.52B for the twelve trailing months.

Coca Cola Femsa S.A.B. de C.V. 's sales growth for the next quarter is 30.6%. The company's growth estimates for the present quarter and the next is 8.2% and 65.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.22%.

Volatility

Coca Cola Femsa S.A.B. de C.V. 's last day, last week, and last month's current volatility was 0.65%, 0.87%, and 0.94%, respectively.

Coca Cola Femsa S.A.B. de C.V. 's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.00% (day), 1.73% (last week), and 2.01% (last month), respectively.

Coca Cola Femsa S.A.B. de C.V. 's Stock Yearly Top and Bottom Value

Coca Cola Femsa S.A.B. de C.V. 's stock is valued at $47.84 at 17:22 EST, under its 52-week high of $49.16 and way higher than its 52-week low of $36.16.

Coca Cola Femsa S.A.B. de C.V. 's Moving Average

Coca Cola Femsa S.A.B. de C.V. 's worth is higher than its 50-day moving average of $46.29 and above its 200-day moving average of $44.65.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com